PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,772.00
Bid: 1,771.50
Ask: 1,772.50
Change: -11.50 (-0.64%)
Spread: 1.00 (0.056%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European stocks end four-day winning run as UK's FTSE drags

Thu, 13th Aug 2020 09:39

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* FTSE 100 leads declines on ex-dividend trading

* Cyclical sectors hand back some of this week's gains

* Thyssenkrupp slides on flagging losses in steel unit

* TUI sinks to 1 bln euro loss in Q3
(Updates to market close)

By Sruthi Shankar and Sagarika Jaisinghani

Aug 13 (Reuters) - European stocks broke a four-day winning
streak on Thursday as ex-dividend trading and a stronger pound
hit the UK's blue-chip companies, while investors sold off banks
and energy stocks that have outperformed this week.

The pan-European STOXX 600 closed 0.6% lower, with
London's FTSE 100 sliding 1.5% as a jump in the pound
hurt exporters on the index, while heavyweights like AstraZeneca
, BP, and GlaxoSmithKline traded without
entitlement to a dividend payout, hitting their shares.

Reversing a recent trend, investors favoured pockets of
markets that have remained resilient in the wake of the
coronavirus crisis such as the technology sector. On Wall
Street, Apple was set to record $2 trillion in market
capitalisation.

That left some of the cyclical sectors that are more exposed
to an economic downturn, such as banks, oil & gas
, miners and automakers, falling between
0.8% and 1.9%.

Geir Lode, head of global equities international at
Federated Hermes, noted that it is difficult to gauge whether a
rally in these cheaper stocks will be sustained.

"It reflects the uncertainty that still pervades the world
as we continue to negotiate our way back to normality as well as
increasing U.S.-China tensions," Lode wrote in a note.

After a U.S. move to ban two popular Chinese apps last week,
investors were nervous about upcoming talks between Beijing and
Washington officials over a trade deal agreed earlier this year.

Meanwhile, U.S. Democrats and Republicans remain deadlocked
after weeks of wrangling over a fifth coronavirus aid bill to
support a struggling economy.

Trillions of dollars in stimulus and a stellar rally in
technology stocks have helped the U.S. S&P 500 index
reach striking distance of a record high. The European blue-chip
index is still about 15% below its February peak, but
the pace of recovery for both from a market crash in March has
been similar.

Weak earnings also dented the mood, with struggling
conglomerate Thyssenkrupp plunging 16.3% after it said
its steel unit would rack up 1 billion euros ($1.2 billion) in
operating losses this year, raising pressure to fix or sell the
division.

TUI, the world's largest tourism company, fell 6.2%
as it sank to a 1.1 billion euro ($1.30 billion) loss in the
third quarter due to the COVID-19 pandemic.

Danish brewer Carlsberg slid 5.8% on a warning
that lockdowns will impact sales in the second half of the year
in its key markets of China and Western Europe.

(Reporting by Sruthi Shankar in Bengaluru; Additional reporting
by Sagarika Jaisinghani; Editing by Arun Koyyur, Bernard Orr and
Giles Elgood)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.